A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.

@article{Hammer1997ACT,
  title={A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.},
  author={Scott M. Hammer and Kathleen E. Squires and Michael R. Hughes and Jill M Grimes and Lisa M. Demeter and Judith Silverstein Currier and Joseph J Eron and Judith E. Feinberg and Henry H. Balfour and Lawrence R. Deyton and Jeffrey A Chodakewitz and Margaret A Fischl},
  journal={The New England journal of medicine},
  year={1997},
  volume={337 11},
  pages={725-33}
}
BACKGROUND The efficacy and safety of adding a protease inhibitor to two nucleoside analogues to treat human immunodeficiency virus type 1 (HIV-1) infection are not clear. We compared treatment with the protease inhibitor indinavir in addition to zidovudine and lamivudine with treatment with the two nucleosides alone in HIV-infected adults previously treated with zidovudine. METHODS A total of 1156 patients not previously treated with lamivudine or protease inhibitors were stratified… CONTINUE READING